-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 22, Eli Lilly and Company partnered with ProQR
Therapeutics jointly announced the expansion of its licensing and collaboration agreement to expand collaboration on RNA editing technologies with a focus on the discovery, development and commercialization
of new gene drugs.
Affected by this news, ProQR Therapeutics' share price jumped 63.
64% on the day, and now has a total market value of $193 million
.
64%
Under the terms of this expanded agreement, Eli Lilly will use ProQR's Axiomer® RNA
Edit the platform to obtain other targets
of the central nervous system and peripheral nervous system.
Eli Lilly will make an upfront payment of $75 million and equity investments, as well as an option to further expand the partnership for a consideration of $50 million
.
In addition, Eli Lilly has the option to provide ProQR with access to the company's proprietary delivery technology that can be used in its wholly-owned pipeline
.
.
$75 million, $50 million
Under its original and expanded agreements, ProQR is eligible for research, development and commercialization milestones of up to approximately $3.
75 billion, as well as tiered royalties
of up to mid-single-digit product sales.
75 billion
Original English text: _mstmutation="1" _msthash="220730" _msttexthash="10499125">
